about
A review of anti-inflammatory agents for symptoms of schizophreniaLyme disease and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS): an overviewCelecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On TrialsAceruloplasminemia With Psychomotor Excitement and Neurological Sign Was Improved by Minocycline (Case Report)Missing and Possible Link between Neuroendocrine Factors, Neuropsychiatric Disorders, and MicrogliaA novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation [corrected] factor eIF4AI.Brain microglial cytokines in neurogenic hypertensionEffectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review.Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial.Effects of minocycline on cocaine sensitization and phosphorylation of GluR1 receptors in 5-lipoxygenase deficient miceBiotic acts of antibioticsNeurodegeneration in schizophrenia.Immunomodulatory effects of antimicrobial agents. Part I: antibacterial and antiviral agents.Glutamatergic agents for schizophrenia: current evidence and perspectives.Antipsychotic-like effect of minocycline in a rat model.Eosinophil chemotactic chemokine profilings of the brain from permissive and non-permissive hosts infected with Angiostrongylus cantonenis.Does minocycline, an antibiotic with inhibitory effects on microglial activation, sharpen a sense of trust in social interaction?Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia.
P2860
Q22241827-D4EA4A94-BB5F-482A-B40F-52F2C0A4ED53Q24626864-E573DEC6-1B25-48C4-BA7E-6BDFD506544EQ26741541-0C56024D-BDAA-4DBC-ABFF-CBA70D3374B3Q28830683-EA643F51-6131-4EEB-AAF9-F1BA2BC7583FQ30452038-FF6CA8A1-A101-4B6E-94D1-8546C6B999BBQ33769000-C9C2A16B-D176-48DE-8CFF-868F9B251AFBQ34089804-3225FE33-C44A-43D9-8206-0F18E279ABADQ34384181-6B72C558-CAAF-4037-8A25-F05C4BC11477Q34464608-E201883D-0D49-40C5-A900-187AA5D3D286Q34482249-191BCE82-8437-4EC1-94C2-F118007F5CF6Q37101851-65C0DF04-5C1A-4006-980C-72B95829636FQ37768444-2113FCF7-0B5E-473F-A70E-324B74639A4EQ37991389-9C27960D-0654-4C19-9AF5-447C8274E416Q38444551-DC31C2A3-D35B-4D0B-B450-0B225DC24330Q43015622-595AEA2F-389E-4B89-8165-E5A7AFF3E822Q48872236-CC7FE7F7-131C-4400-A0C4-DAE859B011E8Q48873818-2BA08560-D781-4D32-B52A-2CA44936A9D0Q50653774-C4567DF0-6DBB-479E-BA2E-3FFE21A0E784
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Clinical potential of minocycline for schizophrenia.
@ast
Clinical potential of minocycline for schizophrenia.
@en
Clinical potential of minocycline for schizophrenia.
@nl
type
label
Clinical potential of minocycline for schizophrenia.
@ast
Clinical potential of minocycline for schizophrenia.
@en
Clinical potential of minocycline for schizophrenia.
@nl
prefLabel
Clinical potential of minocycline for schizophrenia.
@ast
Clinical potential of minocycline for schizophrenia.
@en
Clinical potential of minocycline for schizophrenia.
@nl
P1476
Clinical potential of minocycline for schizophrenia.
@en
P2093
Tsuyoshi Miyaoka
P304
P356
10.2174/187152708786441858
P577
2008-10-01T00:00:00Z